Skip to main
ATXS
ATXS logo

Astria Therapeutics (ATXS) Stock Forecast & Price Target

Astria Therapeutics (ATXS) Analyst Ratings

Based on 9 analyst ratings
Buy
Strong Buy 33%
Buy 67%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Astria Therapeutics Inc is positioned favorably in the biopharmaceutical landscape due to its promising product pipeline, particularly STAR-0215 and STAR-0310, which are addressing significant unmet needs in hereditary angioedema and atopic dermatitis, respectively. The preliminary data for STAR-0215 shows a remarkable 90-95% reduction in mean monthly attack rates, indicating strong efficacy and offering a unique prophylactic role that could enhance patient compliance through extended dosing. Additionally, STAR-0310 exhibits superior binding affinity and efficacy compared to existing treatments, showcasing its potential to lead in the market with differentiated therapeutic benefits.

Bears say

Astria Therapeutics's financial outlook appears negative due to several critical factors, including the risk of failed clinical trials and potential funding shortfalls that may inhibit the advancement of its drug candidates. The company's recent financial results for Q4 2024 showcased a larger-than-expected loss per share, with EPS reported at ($0.44) against estimates of ($0.50) and a consensus of ($0.45), indicating persistent challenges in meeting financial expectations. Additionally, competitive pressures and a modest efficacy/safety profile for its products compared to market leaders further exacerbate the risks associated with its stock performance.

Astria Therapeutics (ATXS) has been analyzed by 9 analysts, with a consensus rating of Buy. 33% of analysts recommend a Strong Buy, 67% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Astria Therapeutics and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Astria Therapeutics (ATXS) Forecast

Analysts have given Astria Therapeutics (ATXS) a Buy based on their latest research and market trends.

According to 9 analysts, Astria Therapeutics (ATXS) has a Buy consensus rating as of Aug 25, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $27.89, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $27.89, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Astria Therapeutics (ATXS)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.